Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

treprostinil diolamine

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Pulmonary arterial hypertension (PAH) is a progressive condition that can lead to right ventricular failure and death… Expand
  • table 1
  • table 2
  • table 3
2014
2014
Pulmonary arterial hypertension (PAH) is a rare yet progressive and life-threatening condition that, despite the availability of… Expand
2014
2014
Pulmonary arterial hypertension (PAH) is a rare yet progressive and life-threatening condition that, despite the availability of… Expand
Highly Cited
2013
Highly Cited
2013
Background— Pulmonary arterial hypertension (PAH) is a progressive, fatal disease with no cure. Parenteral and inhaled… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2013
2013
Abstract: Pulmonary arterial hypertension (PAH) is a progressive vascular disease that ultimately leads to right ventricular… Expand
2013
2013
Treprostinil diolamine (oral treprostinil) is a prostacyclin analogue under evaluation for the treatment for pulmonary arterial… Expand
2013
2013
Abstract: Treprostinil diolamine sustained release (UT-15C SR) is being evaluated as an oral therapy for pulmonary arterial… Expand
2013
2013
Treprostinil diolamine (oral treprostinil) is a prostacyclin analogue currently being evaluated for the treatment of pulmonary… Expand
2013
2013
Abstract: Treprostinil, a stable prostacyclin analogue used in the treatment of pulmonary arterial hypertension, is in… Expand
2013
2013
P ulmonary arterial hypertension (PAH) is a devastating and progressive disease of the pulmonary circulation, characterized by… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4